3SBio and Alexandria Venture Investments have both contributed to a $50m round raised by Verseau, which is developing immunotherapies based on MIT research.

Verseau Therapeutics, a US-based cancer immunotherapy spinout of Massachusetts Institute of Technology, launched with $50m in funding yesterday from investors including biotechnology producer 3SBio and life sciences real estate investment trust Alexandria Real Estate Equities.
The round also featured 20/20 HealthCare Partners, Highlight Capital, Yonghua Capital, InHarv Partners and Mark Foundation for Cancer Research, while Alexandra Real Estate Equities participated through its Alexandria Venture Investments unit.
Founded in 2017, Verseau is working on immunotherapies that reprogram macrophages – large…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in